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Purpose: To determine the consequences of the chronic use of systemic corticosteroids in children with juvenile rheumatoid
arthritis by means of evaluating osteochondral effects depicted by magnetic resonance imaging.
Patients and Methods: We reviewed clinical and magnetic resonance imaging findings in 69 children (72 knees) with juvenile
rheumatoid arthritis. Two groups were studied. Group I: 34 (49.3%) children had previous or current use of systemic corticotherapy
(22 girls; 12 boys; mean age: 11.3 years; mean disease duration: 5.9 years; mean corticotherapy duration: 2.9 years; mean cumulative
dose of previous corticosteroids: 5000 mg); Group II: 35 (50.7%) children had no previous use of corticosteroids (27 girls; 8 boys;
mean age: 11.7 years; mean disease duration: 5.3 years). The groups were compared statistically.
Results: In the group that had received corticotherapy (Group I), osteochondral abnormalities were significantly correlated to
long-standing disease (>3.5 years; p<0.001). This correlation was not found in the group that had no previous history of corticotherapy
(Group II). No correlations were established between median dose of corticosteroids and magnetic resonance imaging findings.
Conclusion: It is important to further investigate the long-term intra-articular effects of systemic corticotherapy to ensure that
the side effects of the aggressive therapy will not be more harmful for the joints than the symptoms suffered over the natural course
of the disease.
DESCRIPTORS: Systemic corticotherapy. Juvenile rheumatoid arthritis. Children. Knee. Magnetic resonance imaging.
Juvenile rheumatoid arthritis (JRA)
is a relatively common childhood dis-
ease characterized by chronic arthritis1,
with a prevalence in developed coun-
tries of approximately 1 in 1000 chil-
dren2. Synovitis is responsible for the
development of synovial hypertrophy
(pannus) that can erode articular carti-
lage and bone and invade the adjacent
bone marrow space, leading to joint
deformity and producing much of the
morbidity and disability in the dis-
ease3,4. For those children who do not
respond to salicylates and nonsteroid
anti-inflammatory drugs, corticoster-
oids and other immunosuppressive
agents may be required for manage-
ment of the disease.
Radiography does not provide in-
formation about the status of osteo-
chondral structures before cartilage is
damaged5. On the other hand, magnetic
resonance imaging (MRI) provides ex-
quisite distinction of bone and soft tis-
sue in the articular structures3-6 and is
a highly sensitive tool for establishing
the diagnosis of JRA7.
The systemic side effects of long-
term corticotherapy in children are
well-established8. To justify chronic
use of corticotherapy, the therapy’s
benefits must offset not only the risks
of the disease itself but also its own ad-
verse side effects. Although there is
little doubt that the use of systemic
corticotherapy improves the signs and
symptoms of rheumatoid arthritis in
most patients, it is uncertain whether
over long-term use it can produce more
adverse effects on joints than other
drug treatment regimens. Careful con-
sideration of long-term systemic
corticotherapy is mandatory not only
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because of its known systemic side ef-
fects, but also because of the drug-in-
duced intra-articular changes.
This study investigates the MRI
findings, rather than the traditionally
used radiographic findings, in a cross-
section of JRA patients with varying
durations of the disease who had or not
undergone previous corticotherapy.
The purpose of our study was to estab-
lish correlations among the presence of
synovial and osteochondral abnormali-
ties demonstrated by MRI, disease ac-
tivity at the time of exam, and previ-
ous and/or current systemic
corticotherapy.
PATIENTS AND METHODS
Sixty-nine children with clinically
proven JRA, according to the classifi-
cation criteria of the American College
of Rheumatology9 were selected for the
study. Disease duration at the time of
MRI performance ranged from 5
months to 14 years (mean: 5.6 years).
Two groups of patients with JRA were
analyzed. Group I included 34 (49.3%)
patients who had a previous or current
history of corticotherapy. In this group,
we analyzed 36 knees. Group II in-
cluded 35 (50.7%) patients who were
using either no medication or drug
therapy other than corticosteroids. We
studied 36 knees in this group.
Patient Characteristics
In Group I, 22 (64.7%) patients
were girls and 12 (35.3%) were boys.
Their mean age was 11.3 (range: 4.8-
17.1) years, mean disease duration was
5.9 years, mean duration of
corticotherapy was 2.9 years, and me-
dian total dose of corticosteroids pre-
viously used was 5000 (range: 225-
40283) mg. Among Group I patients,
11 (32.4%) presented clinical activity
at the time of exam as defined by the
presence of arthritis in any joint5.
Twenty-two (64.7%) patients had sys-
temic disease, 10 (29.4%) had pol-
yarticular disease, and 2 (5.9%) had
pauciarticular disease.
In this group, clinical indication for
use of systemic corticotherapy had
been based on severe manifestations of
the disease, including pericarditis,
myocarditis, vasculitis, and hemoph-
agocytic syndrome. The dose of corti-
costeroids was adjusted to the clinical
and laboratory severity of disease.
Group I was further subdivided accord-
ing to duration of corticotherapy:
Group IA had 1 year corticotherapy
and Group IB had >1 year. We also
compared the results within each group
between those patients with prolonged
disease duration (>3.5 years) and those
with shorter duration of disease (3.5
years).
In Group II, there were 27 (77.1%)
girls and 8 (22.9%) boys; their mean
age was 11.7 (range: 2.6-20) years, and
mean disease duration was 5.3 years.
Among these children, 10 (28.6%) pre-
sented clinically active disease. Eleven
(31.4%) patients had systemic disease,
9 (25.7%) had polyarticular disease,
and 15 (42.9%) had pauciarticular dis-
ease.
Magnetic Resonance Imaging (MRI)
We performed MRI on the knees of
all patients included in this study us-
ing a 1.5-T magnet, a whole volume
extremity coil, and the imaging param-
eters listed in table 1. Gadolinium was
injected intravenously at a dosage of
0.1mmol/kg. The images were evalu-
ated independently by 2 experienced
radiologists who were blinded to the
clinical history or plain films and di-
rected to evaluate: (1) the presence of
synovial proliferation in the suprapatel-
lar bursa—eg, synovial enhancement
post-gadolinium; (2) the presence of
osteochondral abnormalities—eg, sub-
chondral cysts, marginal erosions, and/
or bone marrow edema; (3) both of the
above findings, and (4) absence of
depictable lesions.
Statistical Analysis
Correlations among MRI findings
and (1) disease duration (ie, 3.5 years
Table 1 - Pulse sequences used for analysis of MRI findings.
Series TR TE Slice thickness/gap Flip angle FOV Matrix Time
(ms) (ms) (mm) (0) (min)
Sagittal IW SE 1800 20 4.0 / 0.4 90 180 179 x 256 03:07
Sagittal T2 SE 1800 85 4.0 / 0.4 90 180 179 x 256 03:07
Coronal T1 SE 25 20 4.0 / 0.0 90 180 179 x 256 03:18
Coronal T2 FFE 40 14 4.0 / 0.0 10 180 179 x 256 01:32
Coronal T1 SE (post-gad.) 525 20 4.0 / 0.0 90 180 179 x 256 03:18
Sagittal T1 SE (post-gad.) 525 20 4.0 / 0.4 90 180 179 x 256 01:52
Axial T1 SE (post-gad.) 525 20 4.0 / 0.4 90 180 179 x 256 03:22
Axial T1 SPIR SE (post-gad.) 525 20 4.0 / 0.4 90 180 179 x 256 05:02
TR = time repetition; TE = time echo; ms = milliseconds; min = minutes; post-gad. = post-gadolinium; SE = spin-echo; FOV = field-of-view;
IW = intermediate-weighted; SPIR = spectral presaturation with inversion recovery
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or >3.5 years), (2) clinical activity of
disease, (3) previous use of corticoster-
oids, (4) duration of corticotherapy, (5)
dose of systemic corticosteroids, and
(6) type of osteochondral changes were
analyzed using the Fisher's exact test
(2-tail)10, with a p value < 0.05 indi-
cating statistical significance.
RESULTS
In Group I patient's joints
(n1=number of joints) with disease du-
ration longer than 3.5 years (n1 = 23),
MRI depicted osteochondral changes
both with (n1=14) and without (n1=3)
associated synovial proliferation in 17
joints (Fig. 1 and Table 2). Four of
these patients had clinically active dis-
ease. In Group II children with
longstanding disease (n1 = 21), 17 pa-
tients demonstrated cartilaginous ab-
normalities both with (n1=15) and
without (n1=2) associated synovial
changes (Fig. 2 and Table 2). Eight of
these children had clinically active dis-
ease.
Although the results between these
two groups are comparable, significant
differences in MRI findings with re-
gard to osteochondral lesions and syn-
ovial enhancement in patients with
long and short disease duration were
demonstrated only in Group I
(p<0.001). In Group II, we did not find
any significant relationship between
disease duration (ie, 3.5 years or >3.5
years) and the 4 parameters analyzed
by MRI (p=0.076), nor between the
presence of osteochondral changes and
clinical disease activity in any of the
groups. However, we did find a signifi-
cant difference between MRI findings
of osteochondral abnormalities accord-
ing to disease duration (p<0.001)
(Table 2) in Group I patients. In this
group (n1 = 36), among the 18 patients
in whom MRI demonstrated osteo-
chondral lesions, changes were more
often associated with synovial prolif-
eration (Fig. 1A) than seen as isolated
findings (Fig. 3A). Fifteen of these
children demonstrated such prolifera-
tion (p<0.001) (Table 2).
When we analyzed results accord-
ing to disease duration for children
with >3.5 years of disease in Group I
patients (n1 = 23), presence of osteo-
chondral lesions associated with syn-
ovial proliferation was the most com-
mon finding, demonstrated in 14
(60.9%) knees. In contrast, in patients
with at least 3.5 years of the disease
(n1 = 13) this finding was demon-
strated in only 1 joint (Table 2).
Regarding the effects of the dura-
tion of corticosteroid treatment, we
found a significant increase in osteo-
chondral changes and synovial hyper-
trophy in children receiving corticos-
Table 2 - Correlations between MRI findings and disease duration in joints of Group I and II patients.
Disease Duration
MRI Findings (Group I)  3.5 years > 3.5 years Total
Osteochondral lesions 0 (0%) 3 (100%) 3
Synovial enhancement 6 (54.55%) 5 (45.45%) 11
Synovial enhancement and osteochondral lesions 1 (6.67%) 14 (93.33%) 15
No osteochondral/synovial pathologic findings 6 (85.71%) 1 (14.29%) 7
Total (number of joints) 13 23 36
Fisher's exact test (2-tail) p<0.001
Disease duration
MRI findings (Group II)  3.5 years > 3.5 years Total
Osteochondral lesions 1 (33.33%) 2 (66.67%) 3
Synovial enhancement 4 (66.67%) 2 (33.33%) 6
Synovial enhancement and osteochondral lesions 5 (25%) 15 (75%) 20
No osteochondral/synovial pathologic findings 5 (71.43%) 2 (28.57%) 7
Total (number of joints) 15 21 36
Fisher's exact test (2-tail) p=0.076
Figure 1 - An example of longstanding disease (12-year duration) in a 17-year-old boy with a previous
5.6-year use of systemic corticotherapy, as represented by (A) a sagittal T1-weighted SE image and
(B) a coronal T1-weighted SE image obtained after gadolinium administration. Note the osteochondral
abnormalities demonstrated by subchondral cysts (black arrows), bone erosion (black arrowhead),
and zones of bone marrow hyperemia within the epiphysis (open arrow) associated with thickening
of the synovial lining of the suprapatellar bursa (curved arrow).
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teroids for more than 1 year, as com-
pared with children receiving corticos-
teroids for less than 1 year. In the
group of patients using corticosteroids
for >1 year (n1 = 23), osteochondral
changes were seen in 13 children, and
in all 13 cases, synovial hypertrophy
was also present. In the patients using
corticotherapy for at least 1 year (n1 =
13), osteochondral changes were seen
in 5 joints, in 3 as the only finding, and
in 2 associated with synovial prolifera-
tion, (p=0.015) (Table 3).
No statistically significant differ-
ences were noted between MRI find-
ings according to the total dose of sys-
temic corticotherapy previously used in
any of the Group I patients analyzed (n
= 33) (p=0.205) (Table 4). Three pa-
tients, each having 1 joint analyzed,
were not included in this analysis be-
cause of inconclusive data from clini-
cal history and follow-up.
Table 5 outlines relationships be-
tween types of osteochondral abnor-
malities and MRI findings. A strong
relationship was obtained in Group I
(p<0.0001) but not in Group II. The
majority of cartilaginous lesions were
seen along with synovial proliferation
in both Group I (n1 = 16) and Group
II (n1 = 20). The most common osteo-
chondral findings were the association
of bone erosions and subchondral cysts
in Group I (n1 = 9) (Fig. 3B) and iso-
lated bone erosions in Group II (n1 =
15).
DISCUSSION
Because of its excellent soft tissue
contrast, MRI allows detection of early
articular changes5,6,11,12 and provides in-
formation for both diagnostic3,7,13 and
therapeutic purposes14-19. Before the
advent of MRI, radiography was the
only noninvasive method available for
direct visualization of bone changes in
joints and was the “gold standard” mo-
dality for identification of progression
in rheumatoid arthritis20-25. Since the
1950s, much concern has been ex-
pressed about the effects of medication
used in this disease which has led to
large multicenter trials, such as those
comparing the effects of oral steroids
Figure 2 - Example of longstanding arthritis (12-year duration) in an 18-year-old girl with polyarticular
JRA with no previous use of systemic corticotherapy, represented by post-gadolinium MRI images
of (A) an axial T1-weighted SE and (B) an axial fat-suppressed, T1-weighted SE sequence. Note the
corresponding appearance of enhancing synovium (black arrows) and subchondral cyst on patella
(white arrow) in panel A. In the axial fat-suppressed, T1-weighted SE image, the full extension of the
hypertrophied synovium is masked by surrounding enhanced vessels (asterisk). This example shows
that the natural progression of disease, independently of concomitant systemic therapy, may lead to
formation of subchondral cysts. This evidence suggests that other factors than corticotherapy use –
including natural progression of disease – may be responsible for osteochondral damage.
Figure 3 - Osteochondral abnormalities, without synovial enhancement, are seen in this 17-year-old
boy with continuous use of systemic corticotherapy for 7 months in a longstanding course of the
disease (14 years) represented by post-contrast MRI images of the (A) sagittal T1-weighted SE and
(B) coronal T2-weighted FFE sequences. In Figure 3A, note the subchondral cysts (black arrows)
that can be demonstrated within the femoral and tibial epiphysis. The coronal T2-weighted FFE
sequence in Figure 3B underestimates the area of the subchondral cyst (white arrows), since the
peripheral aspect of the cyst has the same signal intensity as adjacent bone marrow. On this sequence,
bone marginal erosions are difficult to discern (open arrow). This case demonstrates that although
both disease and corticotherapy duration in Group I may be responsible for the destructive changes
in the knees, long disease duration (natural progression of disease) seems to play a more important
role in the development of osteochondral abnormalities in JRA than long-term corticotherapy.
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mide and gold would retard the radio-
graphic progression of joint destruc-
tion. Nevertheless, the long-term ef-
fects of prolonged corticotherapy are
still not completely clear because of the
consideration of confounding variables
such as severity of disease that affects
both steroid use and osteochondral
damage.
In this study, we found significant
relationships between the MRI find-
ings, including presence of osteochon-
dral abnormalities (subchondral cysts
and/or bone erosions), and disease du-
ration in Group I (children with previ-
ous history of corticotherapy); how-
ever, no such relationship was found
for Group II (children with no previ-
ous history of corticotherapy). Pro-
longed use of systemic corticosteroids
(>1 year) also seemed to be related to
a higher degree of deleterious effects
on the cartilage, although no significant
relationship to the total dose of corti-
costeroids used during treatment was
determined. Moreover, we found no
evidence of a relationship between os-
teochondral changes depicted on MRI
and disease activity at the time of MRI
performance either for Group I or for
Group II. The use of systemic
corticotherapy in the group of patients
with more aggressive disease suggested
the possibility of an interaction be-
Table 5 - Correlation between types of osteochondral changes and MRI abnormalities in the joints of Group I and II patients.
MR findings (Group I) SC Er + SC Er Absence Total
Osteochondral lesions 0 (0%) 1 (50%) 1 (50%) 0 (0%) 2
Synovial enhancement 0 (0%) 0 (0%) 0 (0%) 11 (100%) 11
Synovial enhancement and osteochondral lesions 2 (12.5%) 8 (50%) 5 (31.25%) 1 (6.25%) 16
No osteochondral/synovial pathologic findings 0 (0%) 0 (0%) 0 (0%) 7 (100%) 7
Total (number of joints) 2 9 6 19 36
Fisher's exact test (2-tail) p<0.0001
MR findings (Group II) SC Er + SC Er Absence Total
Osteochondral lesions 0 (0%) 0 (0%) 3 (100%) 0 (0%) 3
Synovial enhancement 0 (0%) 0 (0%) 0 (0%) 6 (100%) 6
Synovial enhancement and osteochondral lesions 0 (0%) 8 (40%) 12 (60%) 0 (0%) 20
No osteochondral/synovial pathologic findings 0 (0%) 0 (0%) 0 (0%) 7 (100%) 7
Total (number of joints) 0 8 15 13 36
Fisher's exact test (2-tail) p=0.526
SC= subchondral cysts; Er + SC = bone erosions associated to subchondral cysts; Er = bone erosions; Absence = no lesions
Table 4 - Correlations between MRI findings and total dose of systemic corticotherapy used during
treatment of JRA in the joints of Group I patients.
Corticotherapy Group Cummulative dose of systemic
corticosteroids (mg)
MR findings  5000 > 5000 Total
Osteochondral lesions 3 (100%) 0 (0%) 3
Synovial enhancement 6 (54.55%) 5 (45.45%) 11
Synovial enhancement and osteochondral lesions 4 (30.77%) 9 (69.23%) 13
No osteochondral/synovial pathologic findings 3 (50%) 3 (50%) 6
Total (number of joints) 16 17 33
Fisher's exact test (2-tail) p=0.205
Frequency missing = 3
Table 3 - Correlations between MRI findings and duration of systemic corticotherapy in the joints of
Group I patients.
Systemic use duration
MR findings (CG)  1 year > 1 year Total
Osteochondral lesions 3 (100%) 0 (0%) 3
Synovial enhancement 4 (36.36%) 7 (63.64%) 11
Synovial enhancement and osteochondral lesions 2 (13.33%) 13 (86.67%) 15
No osteochondral/synovial pathologic findings 4 (57.14%) 3 (42.86%) 7
Total (number of joints) 13 23 36
Fisher's exact test (2-tail) p=0.015
to effects of aspirin26-31. As an example
of such effects, adults treated with sys-
temic or intra-articular corticosteroids
have demonstrated disturbances of en-
dogenous cortisol synthesis, including
Cushing’s syndrome32.
There are recent studies about the
local effects of intra-articular injection
of corticosteroids14-17, 33, but few are
about the intra-articular results follow-
ing prolonged systemic corticotherapy.
In 1990, Wilske and Healey19 proposed
an aggressive treatment plan for cases
of destructive rheumatoid arthritis.
Their study included the use of mul-
tiple medications, including oral ste-
roids, and challenged the conventional
treatment that employed a slow,
stepwise addition of medications34-37. A
few years earlier, Iannuzzi et al.38
found evidence through radiographic
assessment that both cyclophospha-
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tween the severity of disease and osteo-
chondral abnormalities rather than be-
tween abnormalities and therapeutic
medication. However, it was not pos-
sible to establish statistically significant
relationships between presence or ab-
sence of lesions and previous use or
lack of use of systemic corticotherapy,
regardless of disease duration. Never-
theless, our results corroborate previ-
ous radiological studies39-41, providing
the possibility that over the course of
the disease more severe deformities in
articular joints could be produced fol-
lowing treatment with corticosteroids.
Because MRI allows identification of
subtle cartilaginous abnormalities very
early, we were able to show the abnor-
malities in an earlier period of disease
than previous radiological studies have
shown. A limitation of this and previ-
ous studies using radiographies is the
difficulty to know whether patients re-
ceiving steroids were already at higher
risk of developing osteochondral ab-
normalities, since they would belong to
a more aggressive spectrum of JRA,
which is bound to bias the results.
The goal of therapy for JRA is to
retard clinical and radiographic joint
degeneration, but the adverse systemic
and intra-articular effects of long-term
treatment should not outweigh the pur-
pose of systemic therapy. Another
point of concern is the disparity be-
tween the clinical improvement in pa-
tients following systemic medications
and the worsening of radiographically
diagnosed damage. Our study evalu-
ated children with JRA who received
short- and long-term systemic corticos-
teroids, comparing them with a
noncorticotherapy group to determine
the osteochondral abnormalities in the
knees according to duration of immu-
nosuppressive therapy. We did not con-
sider other concurrent or confounding
variables, such as combined therapy,
that could influence the progression of
articular damage in either Group I or
Group II.
Numerous questions raised by this
study reflect the problem of distin-
guishing between effects of disease and
effects of corticosteroids. Does sys-
temic corticotherapy produce addi-
tional and different changes than those
caused by the disease? Were our results
a consequence of the fact that the pa-
tients given corticotherapy already had
more destructive disease? Do these os-
teochondral abnormalities also develop
in non-rheumatoid experimental
models given long-term systemic
corticotherapy for other conditions?
It is possible that intra-articular cor-
tisone injections that result in long-last-
ing relief of symptoms with minor or
few side effects17,42,43 could decrease the
need for systemic corticosteroids in the
management of JRA.
Rheumatologists treating children
with JRA must balance two opposing
realities. First, prolonged cortico-
therapy will invariably cause adverse
systemic and articular effects in a spec-
trum of disease that does not carry the
threat of mortality as, for example, ma-
lignancies do. Second, a patient not
given aggressive treatment after unag-
gressive management is unsuccessful
may suffer a lifetime of disability and
functional impairment. Currently, labo-
ratory data can identify those patients
at greatest risk for destructive disease
who should be treated more aggres-
sively. However, this study suggests
that after remission of the disease,
noncorticotherapy would be preferred
as a maintainance therapeutic strategy.
Our statistical correlations raise the
possibility that systemic corticotherapy
may be a contributing factor in the in-
tra-articular progression of the disease.
However, differences in disease sever-
ity between the corticosteroid-treated
and not-treated groups should be con-
sidered in the interpretation of our re-
sults.
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RESUMO RHCFAP/3045
DORIA AS e col. - Correlação entre as
alterações osteocondrais evidencia-
das à ressonância magnética e a
progressão da doença. Rev. Hosp.
Clín. Fac. Med. S. Paulo 56(4):
107-114, 2001.
Objetivo: Determinar as conse-
qüências do uso crônico de corticos-
teróides sistêmicos em crianças com
artrite reumatóide juvenil através da
avaliação dos efeitos osteocondrais à
ressonância magnética.
Pacientes e métodos: Achados clí-
nicos e imaginológicos (ressonância
magnética) de 72 joelhos em 69 crian-
ças com artrite reumatóide juvenil fo-
ram revisados. Trinta e quatro (49.3%)
pacientes fizeram uso prévio de cortico-
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terapia sistêmica (22 pacientes do sexo
feminino; 12 pacientes do sexo mascu-
lino; idade média: 11.3 anos; duração
média da doença: 5.9 anos; duração
média da corticoterapia: 2.9 anos; dose
média cumulativa de corticosteróides:
5000 mg); 35 (50.7%) pacientes não
haviam feito uso prévio de cortico-
terapia sistêmica (27 pacientes do sexo
feminino; 8 pacientes do sexo masculi-
no; idade média: 11.7 anos; duração
média da doença: 5.3 anos).
Resultados: No grupo que recebeu
corticoterapia sistêmica prévia (Grupo
I) a presença de alterações osteo-
condrais à ressonância magnética rela-
cionou-se de uma forma estatistica-
mente significativa com longo tempo
de duração da doença (>3.5 years;
P<0.001). Tal relação não foi estabe-
lecida no grupo de pacientes sem uso
prévio de corticosteróides sistêmicos
(Group II). Da mesma forma, não hou-
ve relação entre a dose média de
corticosteróides e os achados à resso-
nância magnética.
Conclusão: É importante avaliar-se
os efeitos intra-articulares a longo pra-
zo do uso crônico de corticoterapia
sistêmica em artrite reumatóide juvenil
à ressonância magnética, uma vez que
os efeitos colaterais de uma terapia
agressiva não devem ser potencialmen-
te mais deletérios às articulações que
os efeitos do curso natural da doença.
DESCRITORES: Corticoterapia
sistêmica. Artrite reumatóide juvenil.
Crianças. Joelho. Ressonância
magnética.
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